Financial Performance and Capital Needs - The company has incurred significant operating losses since its inception, with an accumulated deficit of approximately $154.6 million as of December 31, 2025[207]. - The company expects to continue incurring substantial operating losses over the next several years as it develops and seeks regulatory approval for its product candidate, elraglusib[207]. - As of December 31, 2025, the company had approximately $13.2 million in cash and cash equivalents, with working capital of approximately $7.9 million, which is projected to be insufficient beyond July 2026[211]. - The company anticipates needing substantial additional capital to finance its operations and may seek funding through public or private equity, debt financings, or strategic partnerships[212][213]. - The independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern[214]. Product Development and Regulatory Risks - The company relies entirely on the success of elraglusib, which is currently in Phase 2 clinical development for mPDAC, making its business highly dependent on this single product candidate[218]. - The company faces significant risks in obtaining regulatory approvals, which are essential for the commercialization of elraglusib, and any delays could materially harm its business[221][222]. - The company has no approved products on the market and may never achieve profitability if it fails to successfully develop and commercialize elraglusib[221]. - The company acknowledges that the drug development process is lengthy, expensive, and fraught with uncertainty, with a high historical failure rate for product candidates in the biopharmaceutical industry[226]. - The company has not yet demonstrated an ability to overcome the risks and uncertainties associated with biopharmaceutical product development, which complicates its ability to predict future expenses and profitability[210]. - Elraglusib has received Fast Track designation from the FDA for the treatment of pancreatic cancer, which may facilitate the review process but does not guarantee marketing approval[247]. - The company has not yet initiated or completed a Phase 3 clinical trial, which is critical for obtaining FDA approval for elraglusib or any future product candidates[239]. - The company may face significant setbacks in clinical development despite promising early results, as many product candidates fail in later trials[228]. - Enrollment delays in clinical trials could materially affect the company's financial condition and development timelines[238]. - The company may need to conduct additional preclinical studies or clinical trials based on negative or inconclusive results, leading to increased operating expenses and delays[229]. Manufacturing and Supply Chain Challenges - The company relies on a single manufacturer in China for elraglusib's drug substance, and geopolitical factors could impact supply and costs[266]. - The company currently has a sole source manufacturer for the drug substance of elraglusib, which poses risks of supply disruption[278]. - There are no long-term supply agreements in place with suppliers, which could delay clinical trials if supplies are not sourced timely[271]. - The company may face challenges in obtaining regulatory approvals for manufacturing facilities, which could significantly affect product development[270]. - Geopolitical tensions with China could impact the company's ability to conduct clinical trials if relying on Chinese vendors[279]. - The company has limited control over third-party manufacturers' compliance with quality standards, which could affect product quality[269]. - The company is dependent on third parties for conducting clinical trials, which could lead to delays if these parties do not meet their obligations[273]. Intellectual Property Risks - Intellectual property rights may not be enforceable in certain foreign jurisdictions, potentially allowing competitors to exploit the company's innovations[281]. - The company has filed several new composition of matter patent applications for elraglusib, which could expire in 2038, with potential for patent term extensions[283]. - Patent applications in the pharmaceutical and biotechnology sectors may be limited in scope, potentially reducing competitive protection[285]. - The company faces risks of patent expirations, which could diminish competitive advantages and product value[286]. - Trade secrets and proprietary know-how are critical for maintaining competitive position, but their protection is uncertain[287]. - Intellectual property claims may not sufficiently prevent competitors from developing similar products, impacting financial performance[288]. - The company may incur significant costs and time in addressing intellectual property disputes, which could adversely affect business operations[289]. - Changes in patent laws could weaken the company's ability to protect its intellectual property and affect its commercial value[293]. - Patent terms are limited to generally 20 years, which may not provide adequate protection for product candidates like elraglusib[294]. - The company may face claims challenging the inventorship or ownership of its patents, which could result in loss of valuable intellectual property rights[296]. - Third-party intellectual property rights could hinder the commercialization of current or future technologies, requiring potential litigation or licensing[299]. - Infringement claims could lead to substantial damages or force the company to abandon technologies, impacting financial condition and operations[300]. - The company may face claims regarding the wrongful use or disclosure of trade secrets by employees or consultants, which could lead to litigation and substantial costs[301]. - Intellectual property rights may be subject to federal regulations due to government funding, potentially limiting exclusive rights and requiring compliance with reporting requirements[303]. - The U.S. government may have rights to inventions developed under government-funded programs, including the ability to require licensing to third parties if commercialization steps are inadequate[304]. Compliance and Operational Risks - Compliance with healthcare laws and regulations may increase operational costs and expose the company to significant penalties if found in violation[305]. - Strategic transactions, such as acquisitions or partnerships, may incur non-recurring charges and increase near- and long-term expenditures, posing integration challenges[308]. - Cybersecurity incidents could disrupt development programs and compromise sensitive information, potentially leading to significant costs and reputational damage[311]. - The company relies on third-party vendors for IT infrastructure, which may expose it to vulnerabilities if those vendors fail to protect confidential information[313]. - Non-compliance with health privacy and data protection laws could result in government enforcement actions, private litigation, and damage to the company's reputation[315]. - The evolving legal framework around privacy issues may impose new obligations and restrictions on data collection and usage, impacting operational capabilities[318]. - Disruptions at the FDA and other government agencies due to funding shortages and personnel changes could delay the approval and commercialization of new products, negatively impacting the company's business[319]. - The FDA postponed most inspections during the COVID-19 pandemic, and future global health concerns may lead to similar delays, significantly affecting the company's regulatory submissions[320]. - The company's lead drug development program, elraglusib, will be reviewed by the FDA's Center for Drug Evaluation and Research (CDER), which is known for demanding high-quality clinical research[321]. - The company lacks in-house expertise in drug approvals and may rely on consultants, which poses risks of delays and increased expenses in the drug approval process[322]. Stock and Corporate Governance Risks - Approximately 43% of the company's common stock is held by funds affiliated with the chairman, potentially limiting other stockholders' influence and creating conflicts of interest[324]. - The company has never declared or paid cash dividends and does not intend to do so in the foreseeable future, relying on stock price appreciation for returns[331]. - The trading price of the company's common stock is likely to be highly volatile, influenced by clinical trial results, regulatory approvals, and market conditions[329]. - The company may face challenges in maintaining compliance with Nasdaq listing requirements, which could lead to delisting and negatively impact stock price[327]. - The company's amended and restated bylaws contain provisions that could make mergers or proxy contests difficult, potentially depressing stock value[332]. - The company is subject to anti-takeover provisions under Delaware law, which may limit business combinations with significant stockholders[335]. - The company faces significant risks due to unstable market and economic conditions, which may adversely affect its ability to raise funds and could lead to operational delays[338]. - The company is at risk of declining stock price and trading volume if analysts downgrade its stock or cease coverage, impacting investor interest[339]. - The company must maintain effective internal control over financial reporting to ensure accurate financial statements; failure to do so could lead to a decline in stock price and investor confidence[340]. - If the company cannot demonstrate effective internal controls, it may face sanctions from regulatory authorities, which could restrict future access to capital markets[341]. - The company is classified as a "smaller reporting company" and is not required to provide certain market risk disclosures[417].
Actuate Therapeutics,Inc(ACTU) - 2025 Q4 - Annual Report